Silverback: Taking on tumoral myeloid cells

Silverback’s antibody-based conjugates stimulate innate and adaptive immunity by turning myeloid cells against tumors, while overcoming resistance to checkpoint inhibitors and other T cell-targeting immunotherapies.

“When you are able to appropriately and potently activate myeloid cells, the tumor microenvironment is completely reprogrammed,” Valerie Odegard, CSO of Silverback Therapeutics Inc., told BioCentury. “The inflammatory nature of the response allows for T cells and other immune cells to then infiltrate those tumors in a way that wasn’t possible previously.”...